β-Defensin-2 as a Biomarker for Psoriasis
Author Information
Author(s): Jansen Patrick A. M., Rodijk-Olthuis Diana, Hollox Edward J., Kamsteeg Marijke, Tjabringa Geuranne S., de Jongh Gys J., van Vlijmen-Willems Ivonne M. J. J., Bergboer Judith G. M., van Rossum Michelle M., de Jong Elke M. G. J., den Heijer Martin, Evers Andrea W. M., Bergers Mieke, Armour John A. L., Zeeuwen Patrick L. J. M., Schalkwijk Joost
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
Are biologically relevant concentrations of hBD-2 protein present in vivo in psoriasis patients?
Conclusion
Serum hBD-2 is a useful marker for disease activity in psoriasis, with levels correlating strongly with disease severity.
Supporting Evidence
- High systemic hBD-2 levels correlate with disease activity in psoriasis patients.
- Serum hBD-2 levels were significantly higher in psoriasis patients compared to healthy controls.
- The study found a strong linear correlation between PASI score and serum hBD-2 concentration.
Takeaway
This study found that a protein called hBD-2 in the blood can help doctors understand how bad psoriasis is in patients.
Methodology
The study measured serum hBD-2 levels in psoriasis patients and correlated them with disease severity using the PASI score.
Limitations
The study primarily focused on psoriasis patients and may not generalize to other skin conditions.
Participant Demographics
Psoriasis patients were predominantly of native European Dutch origin, with a mean age of 47 years and 42% female.
Statistical Information
P-Value
p<2×10−6
Statistical Significance
p<2×10−6
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website